SYMPTOM DATA

 

BREO—24-hour lasting
symptom control without
a second daily dose

 

24-HOUR BREO DELIVERS IMPROVED SYMPTOM CONTROL.
ALL DAY AND NIGHT.


Based on a 12-week study of patients who remained symptomatic* on a mid- to high-dose ICS,
BREO can offer

 
Study Design
 
Go to BREO 200/25 Adverse Reactions
 
 
 
Study Design
 
Go to BREO 200/25 Adverse Reactions
 
 

In a 24-week study in patients who were symptomatic on a mid- to high-dose ICS,
BREO provided"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"5:

 
Study Design
 
Go to BREO 100/25 Adverse Reactions
 
 
 
Study Design
 
Go to BREO 100/25 Adverse Reactions
 
 

Looking for samples?
Looking for a savings offer?
Subject to eligibility. Restrictions apply.

 

Chat